Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase I Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors

Salubris Biotherapeutics, Inc. announced it has received approval from the European Medicines Agency to initiate a Phase I clinical trial of JK06 in a basket of solid tumors known to express 5T4.